Latest research
Latest corporate research
Latest tax advantaged reviews
Subscribe to our latest research
What we do
Investment research services
Tax enhanced research services
Bespoke consulting services
About
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
Our team
News & events
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
×
Latest corporate investment research
Detailed company analysis created specifically for investors
Latest tax advantaged research
Product reports for investors and advisors
Latest published research
Chesnara Plc
Showing good operational progress
7th Apr 2025
Arbuthnot Banking Group Plc
2024 results: franchise growing through the noise
4th Apr 2025
Services for corporates
Investment research & analysis
Detailed company analysis created specifically for investors
Bespoke valuation services
Bespoke valuation services
Services for clients with specific needs
Services for funds
Tax advantaged research
Product reports for investors and advisors.
About
About Hardman & Co.
We are the longest-established commissioned research provider.
Insights
Group
Created with Sketch.
Podcasts
Group
Created with Sketch.
Videos
Group
Created with Sketch.
Events
Group
Created with Sketch.
See all news
Group
Created with Sketch.
Podcast
The EIS Navigator
Latest Episode
112: How to grow UK venture capital and exciting news | Richard Hoskins of Kin Group
Stay up-to-date with the latest research
Sign up to our newsletter
Life Sciences research
Diurnal Group Plc
Life Sciences
Flow of regulatory approvals
By
Dr Martin Hall
13 Aug 2020
Allergy Therapeutics plc
Life Sciences
Record sales and a COVID-19 wildcard
By
Dr Martin Hall
20 Jul 2020
Stay up-to-date with the latest research
Sign up to our newsletter
Open Orphan
Life Sciences
Investor Forum July 2020: Poised for profitability
By
Dr Martin Hall
02 Jul 2020
Advanced Oncotherapy
Life Sciences
Funded through to clinical events
By
Dr Martin Hall
02 Jul 2020
Incanthera Ltd
Life Sciences
Preparing Sol for commercialisation
By
Dr Martin Hall
19 Jun 2020
Arix Bioscience
Life Sciences
1Q’20 portfolio update
By
Dr Martin Hall
19 May 2020
Shield Therapeutics Plc
Life Sciences
Reassuring trading update
By
Dr Martin Hall
11 May 2020
Arix Bioscience
Life Sciences
Resetting the stage
By
Dr Martin Hall
23 Apr 2020
Diurnal Group Plc
Life Sciences
$52.5m US deal strengthens balance sheet further
By
Dr Martin Hall
30 Mar 2020
Arix Bioscience
Life Sciences
Fiscal 2019 – moving with the times
19 Mar 2020
Allergy Therapeutics plc
Life Sciences
Consistent first-half revenue growth
By
Dr Martin Hall
09 Mar 2020
Prev
1
...
5
6
7
8
9
...
22
Next
